KB103 Investigational Therapy Receives Clearance from RAC Committee
Krystal Biotech recently announced that its leading investigational therapy for epidermolysis bullosa, KB103, has received clearance from the Recombinant DNA Advisory Committee. Krystal Biotech is a gene therapy company developing new therapeutics for dermatological diseases including epidermolysis bullosa. Its lead candidate KB103 is being studied as a potential treatment for dystrophic epidermolysis…